Isaac E. Ciechanover net worth and biography

Isaac Ciechanover Biography and Net Worth

Dr. Isaac Ciechanover is a partner at Polaris, an investment firm that partners with entrepreneurs in healthcare and technology. He joined the firm in 2020 after six years as CEO of Atara Biotherapeutics.

Dr. Ciechanover founded the company in 2012 in honor of his mother, Atara, who passed away from cancer. Atara pioneers T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies. During his tenure as CEO, Dr. Ciechanover led the organization through its IPO and to a valuation over $1 billion.

Previously, he served as a partner in the life sciences practice at Kleiner Perkins Caufield & Byers and in business development positions at Celgene and Amylin Pharmaceuticals. His first foray into venture capital was at the New York firm, Pequot Ventures, right after earning his M.B.A. from Harvard University.

Dr. Ciechanover holds his B.A. in psychology from Stanford, his M. Phil in epidemiology from Cambridge University, and his M.D. from Cornell University’s Weill Medical College.

He is currently based in San Francisco.

What is Isaac E. Ciechanover's net worth?: The estimated net worth of Isaac E. Ciechanover is at least $138,471.38 as of May 30th, 2019. Dr. Ciechanover owns 13,289 shares of Atara Biotherapeutics stock worth more than $138,471 as of December 18th. This net worth approximation does not reflect any other assets that Dr. Ciechanover may own. Learn More about Isaac E. Ciechanover's net worth.
How do I contact Isaac E. Ciechanover?: The corporate mailing address for Dr. Ciechanover and other Atara Biotherapeutics executives is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. Atara Biotherapeutics can also be reached via phone at (805) 623-4211 and via email at [email protected]. Learn More on Isaac E. Ciechanover's contact information.
Has Isaac E. Ciechanover been buying or selling shares of Atara Biotherapeutics?: Isaac E. Ciechanover has not been actively trading shares of Atara Biotherapeutics during the past quarter. Most recently, Isaac E. Ciechanover sold 234 shares of the business's stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $577.25, for a transaction totalling $135,076.50. Following the completion of the sale, the chief executive officer now directly owns 13,289 shares of the company's stock, valued at $7,671,075.25. Learn More on Isaac E. Ciechanover's trading history.
Who are Atara Biotherapeutics' active insiders?: Atara Biotherapeutics' insider roster includes Isaac Ciechanover (CEO), Jakob Dupont (EVP), Matthew Fust (Director), Utpal Koppikar (CFO), K. Murugan (SVP), Joe Newell (Insider), Thomas Peterffy (Chairman), Pascal Touchon (CEO), and Kristin Yarema (Insider). Learn More on Atara Biotherapeutics' active insiders.
Are insiders buying or selling shares of Atara Biotherapeutics?: During the last year, insiders at the biotechnology company sold shares 11 times. They sold a total of 17,499 shares worth more than $204,878.87. The most recent insider tranaction occured on November, 18th when EVP Jill Henrich sold 1,000 shares worth more than $11,200.00. Insiders at Atara Biotherapeutics own 3.7% of the company. Learn More about insider trades at Atara Biotherapeutics.
Information on this page was last updated on 11/18/2024.

Isaac E. Ciechanover Insider Trading History at Atara Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/30/2019	Sell	234	$577.25	$135,076.50	13,289
5/14/2019	Sell	312	$615.25	$191,958.00	13,289
4/26/2019	Sell	312	$838.50	$261,612.00	13,289
4/10/2019	Sell	156	$926.00	$144,456.00	13,289
3/29/2019	Sell	312	$966.50	$301,548.00	13,289
3/15/2019	Sell	312	$987.00	$307,944.00	13,289
2/28/2019	Sell	312	$903.50	$281,892.00	13,289
2/12/2019	Sell	312	$969.25	$302,406.00	13,384
1/24/2019	Sell	312	$876.50	$273,468.00	17,324
1/10/2019	Sell	312	$863.75	$269,490.00	29,331
12/28/2018	Sell	312	$847.00	$264,264.00	29,331
12/27/2018	Sell	156	$826.25	$128,895.00	29,331
12/13/2018	Sell	312	$1,066.50	$332,748.00	29,331
11/29/2018	Sell	312	$1,009.75	$315,042.00	29,331
11/14/2018	Sell	156	$849.75	$132,561.00	29,331
10/22/2018	Sell	156	$844.50	$131,742.00	29,331
10/5/2018	Sell	312	$1,005.50	$313,716.00	29,331
9/19/2018	Sell	312	$995.25	$310,518.00	32,504
9/7/2018	Sell	312	$983.75	$306,930.00	32,504
8/21/2018	Sell	312	$909.25	$283,686.00	32,504
8/7/2018	Sell	312	$935.75	$291,954.00	32,504
7/27/2018	Sell	312	$950.00	$296,400.00	32,504
7/10/2018	Sell	2,336	$1,000.00	$2,336,000.00	32,504
6/26/2018	Sell	176	$1,007.75	$177,364.00	32,504
6/6/2018	Sell	352	$1,214.00	$427,328.00	32,504
5/22/2018	Sell	352	$1,293.50	$455,312.00	32,504
5/10/2018	Sell	352	$996.25	$350,680.00	32,504
4/27/2018	Sell	352	$1,061.50	$373,648.00
4/11/2018	Sell	176	$1,020.50	$179,608.00	32,504
3/26/2018	Sell	176	$1,002.50	$176,440.00	8,259
3/16/2018	Sell	352	$1,053.25	$370,744.00	32,504
3/12/2018	Sell	40	$1,157.75	$46,310.00	32,504
2/22/2018	Sell	712	$1,116.25	$794,770.00	32,504
2/20/2018	Sell	348	$1,132.00	$393,936.00	32,504
2/16/2018	Sell	800	$1,173.00	$938,400.00	32,504
2/14/2018	Sell	800	$1,170.00	$936,000.00	32,347
2/9/2018	Sell	352	$936.00	$329,472.00	32,347
1/26/2018	Sell	772	$881.50	$680,518.00	29,747
1/24/2018	Sell	1,940	$864.50	$1,677,130.00	13,959
1/22/2018	Sell	400	$826.75	$330,700.00	13,959
1/16/2018	Sell	24	$759.50	$18,228.00	29,747
1/12/2018	Sell	1,148	$534.75	$613,893.00	29,747
1/10/2018	Sell	344	$499.75	$171,914.00	29,747
12/29/2017	Sell	888	$457.25	$406,038.00
12/28/2017	Sell	88	$378.75	$33,330.00	29,747
12/13/2017	Sell	176	$366.25	$64,460.00	29,747
11/30/2017	Sell	176	$356.25	$62,700.00
11/14/2017	Sell	176	$336.75	$59,268.00	29,510
10/27/2017	Sell	176	$339.75	$59,796.00	29,510
10/12/2017	Sell	176	$375.50	$66,088.00
10/11/2017	Sell	88	$381.25	$33,550.00	29,510
9/20/2017	Sell	176	$388.50	$68,376.00	29,510
9/7/2017	Sell	176	$375.50	$66,088.00	29,510
8/23/2017	Sell	176	$338.50	$59,576.00	29,510
8/11/2017	Sell	176	$366.75	$64,548.00	29,274
7/25/2017	Sell	220	$412.25	$90,695.00	29,274
7/24/2017	Sell	112	$423.50	$47,432.00	29,274
5/31/2017	Sell	276	$333.75	$92,115.00	29,274
5/30/2017	Sell	138	$336.00	$46,368.00	29,274
5/18/2017	Sell	192	$372.75	$71,568.00	29,274
4/26/2017	Sell	288	$439.00	$126,432.00	29,038
4/25/2017	Sell	144	$433.25	$62,388.00	29,038
4/11/2017	Sell	288	$425.75	$122,616.00	29,038
3/28/2017	Sell	640	$501.50	$320,960.00	29,038
3/17/2017	Sell	1,232	$484.50	$596,904.00	29,038
2/16/2017	Sell	192	$389.00	$74,688.00	29,038
2/3/2017	Sell	192	$341.50	$65,568.00	22,201
1/18/2017	Sell	240	$356.00	$85,440.00	22,201
1/6/2017	Sell	336	$422.25	$141,876.00	22,201
12/23/2016	Sell	192	$380.50	$73,056.00	22,201
12/7/2016	Sell	288	$448.25	$129,096.00	22,201
11/23/2016	Sell	480	$458.50	$220,080.00	22,201
11/22/2016	Sell	336	$455.25	$152,964.00	22,201
10/27/2016	Sell	192	$345.25	$66,288.00	21,965
10/14/2016	Sell	192	$399.00	$76,608.00	21,965
9/28/2016	Sell	480	$521.75	$250,440.00	16,263
9/16/2016	Sell	288	$484.00	$139,392.00	9,165
8/23/2016	Sell	384	$558.25	$214,368.00	9,165
7/21/2016	Sell	384	$552.75	$212,256.00	8,929
7/8/2016	Sell	384	$572.00	$219,648.00	8,929
6/24/2016	Sell	384	$531.50	$204,096.00	8,929
6/8/2016	Sell	480	$513.25	$246,360.00	8,929
6/7/2016	Sell	288	$509.00	$146,592.00	8,929
5/26/2016	Sell	288	$442.25	$127,368.00	8,929
4/26/2016	Sell	52	$503.00	$26,156.00	8,692
4/12/2016	Sell	528	$510.00	$269,280.00	8,692
4/1/2016	Sell	47	$500.75	$23,535.25	8,692
1/14/2016	Sell	96	$505.00	$48,480.00	1,897
12/31/2015	Sell	96	$650.00	$62,400.00	1,897
12/15/2015	Sell	96	$561.50	$53,904.00	1,897
12/4/2015	Sell	160	$936.25	$149,800.00	1,897
11/24/2015	Sell	192	$875.75	$168,144.00	1,897
10/22/2015	Sell	128	$646.25	$82,720.00	1,661
10/7/2015	Sell	160	$827.00	$132,320.00	1,661
9/24/2015	Sell	208	$1,074.75	$223,548.00	1,661
9/11/2015	Sell	208	$1,154.00	$240,032.00	1,661
8/28/2015	Sell	208	$981.25	$204,100.00	1,661
7/17/2015	Sell	208	$1,517.75	$315,692.00
7/1/2015	Sell	208	$1,260.50	$262,184.00
6/18/2015	Sell	208	$1,368.00	$284,544.00
6/5/2015	Sell	256	$1,072.75	$274,624.00
5/22/2015	Sell	160	$939.00	$150,240.00
4/23/2015	Sell	208	$1,534.00	$319,072.00

Isaac E. Ciechanover Buying and Selling Activity at Atara Biotherapeutics

Atara Biotherapeutics Company Overview

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Today's Range

Now: $9.81

$9.68

$10.60

50 Day Range

MA: $10.65

$7.78

$14.26

2 Week Range

Now: $9.81

$6.50

$39.50

Volume

76,980 shs

Average Volume

104,688 shs

Market Capitalization

$56.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol